TNF Inhibitor · Fully Human IgG1 mAb · Anti-TNF-α
Adalimumab Humira®
The first fully human anti-TNF-α monoclonal antibody and a widely studied biologic in TDM research. Pharmacokinetic variability, treatment-emergent anti-drug antibodies and indication-specific exposure–response evidence make adalimumab a strong model for integrated drug and immunogenicity analysis. Six SHIKARI® kits address complementary research questions for the originator and biosimilars.
6
SHIKARI® Kits
96
Tests per kit
3
Analytical Domains
RUO
Research Use Only
Scientific Background
Why Adalimumab is widely studied in TDM research
Adalimumab was first approved in the United States in 2002 and authorised in the European Union in 2003. Its pharmacokinetic variability, treatment-emergent immunogenicity and indication-dependent exposure–response relationships make it an important subject for therapeutic drug monitoring research. FDA source ↗ · EMA source ↗
Mechanism
Molecular Target & Structure
Adalimumab is a fully human IgG1κ monoclonal antibody with a molecular weight of approximately 148 kDa that binds soluble and transmembrane TNF-α. FDA prescribing information ↗
Indications
Approved Indications
EMA-listed uses include rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), Crohn’s disease, ulcerative colitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, hidradenitis suppurativa and non-infectious uveitis. EMA source ↗
Published Evidence
Selected Trough-Level Ranges
Published concentration–response studies report indication- and outcome-specific ranges:
IBD · endoscopic outcomes~7.5–8.1 µg/mL ↗
Rheumatoid arthritis5–8 µg/mL ↗
Plaque psoriasis3.51–7.00 µg/mL ↗
Research-associated ranges, not universal treatment cut-offs. Values vary by endpoint, timing, assay method and population. This page is for RUO product information and does not provide clinical guidance.
SHIKARI® Kit Portfolio
Six complementary research assays
Drug Levels Kit
SHIKARI® Q-ADA
Quantitative Determination of Adalimumab ELISA
REF: ADA-FD-HUM
Enzyme immunoassay for the quantitative determination of adalimumab in serum and plasma. Developed for measuring drug concentration across the Cmin–Cmax range in trough-level and pharmacokinetic research.
Representative Standard Curve
Levels Specific Kit
SHIKARI® QS-ADA
Adalimumab Specific ELISA — Specific & Quantitative Determination of Free Adalimumab (Humira®)
REF: ADA-SPEC-ADA
Anti-idiotype monoclonal antibody-based assay for the specific and quantitative determination of free adalimumab. Distinguishes the pharmacologically active free-drug fraction from drug bound in immune complexes.
Representative Standard Curve
Qualitative ADA Kit
SHIKARI® S-ATA
Qualitative Determination of Antibodies to Adalimumab ELISA
REF: ADA-QLS-HUM
Enzyme immunoassay for the qualitative determination of antibodies to adalimumab in human serum and plasma. Designed for immunogenicity screening in research cohorts.
Quantitative ADA Kit
SHIKARI® S-ATA
Quantitative Determination of Antibodies to Adalimumab ELISA with Confirmation
REF: ADA-QNS-HUM
Enzyme immunoassay with confirmation for the quantitative determination of antibodies to adalimumab in serum and plasma. Supports longitudinal ADA measurement and correlation with drug-level data in research studies.
Representative Standard Curve
Free / Total ADA Kit
SHIKARI® S-ATA Total (Duo)
Semi-Quantitative Free and Total Antibodies to Adalimumab ELISA
REF: ADA-QNFT-HUM
Dual-format kit for parallel measurement of free (unbound) and total (free + drug-complexed) anti-adalimumab antibodies. Includes proprietary dissociation buffer to release ADA from immune complexes — essential for drug-tolerant sample analysis and free-to-total ADA profiling.
Neutralising Ab Kit
SHIKARI® T-CAP NAb™
Target Capture Neutralising Antibodies Immunoassay — Adalimumab
REF: ADA-TCAP-NAb-HUM
Target Capture Neutralising Antibodies immunoassay for the qualitative detection of free neutralising antibodies to adalimumab in human serum and plasma.
Technical Reference
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-ADA | ADA-FD-HUM | Drug Levels | Adalimumab concentration | Ligand-binding assay | 96 | 2–8°C |
| SHIKARI® QS-ADA | ADA-SPEC-ADA | Levels Specific | Specific free adalimumab (anti-idiotype) | Sandwich ELISA | 96 | 2–8°C |
| SHIKARI® S-ATA (Qualitative) | ADA-QLS-HUM | Qualitative ADA | Qualitative anti-adalimumab ADA | Bridging ELISA | 96 | 2–8°C |
| SHIKARI® S-ATA (Quantitative) | ADA-QNS-HUM | Quantitative ADA | Anti-adalimumab ADA | Quantitative immunoassay with confirmation | 96 | 2–8°C |
| SHIKARI® S-ATA Total (Duo) | ADA-QNFT-HUM | Free / Total ADA | Free and total anti-adalimumab ADA | Sandwich assay + dissociation buffer | 96 | 2–8°C |
| SHIKARI® T-CAP NAb™ | ADA-TCAP-NAb-HUM | T-CAP NAb™ | Free neutralising antibodies to adalimumab | Target Capture NAb Assay | 96 | 2–8°C |
Kit Selection Guide
Which kit fits your research question?
Each analytical question in biologic TDM research maps to a distinct assay type.
I need to measure adalimumab drug levels
Use ADA-FD-HUM for routine drug concentration monitoring, or ADA-SPEC-ADA for specific free-drug measurement via anti-idiotype mAb capture.
I need to screen for anti-adalimumab antibodies
Use ADA-QLS-HUM (qualitative bridging ELISA) with validated cut-off controls, suitable for cohort immunogenicity screening.
I need to quantify ADA longitudinally
Use ADA-QNS-HUM (quantitative immunoassay with confirmation) for longitudinal ADA measurement and correlation with drug-level data.
I need to distinguish free ADA from drug-complexed ADA
Use ADA-QNFT-HUM (SHIKARI® S-ATA Total (Duo)) — built-in dissociation buffer for parallel free and total ADA determination in drug-tolerant samples.
I need to determine whether ADA are functionally neutralising
Use ADA-TCAP-NAb-HUM (T-CAP NAb™) for qualitative detection of free neutralising antibodies to adalimumab.
I need a complete adalimumab TDM research panel
All six kits together cover drug levels (standard + specific), qualitative ADA, quantitative ADA titre, free/total ADA profiling, and neutralising antibody characterisation. Contact us for panel pricing.
Scientific Literature
Publications Using SHIKARI® Adalimumab Kits 41
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Kadhim, Ahmed Mansur, Dheyaa Jabbar Kadhim, and Raghad Jawad Hussein. "Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data." Folia Medica 68.2 (2026): e170410.
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (QS-ADA) Adalimumab ELISA (mAb-based)
Kadhim, A. M., Kadhim, D. J., & Hussein, R. J. (2026). Association of novel serum biomarkers (Oncostatin M, 90K/Mac-2 BP, and IL-12 p40) with adalimumab target trough level achievement and response in Iraqi inflammatory bowel disease patients:
Shikari® (QS-ADA) Adalimumab ELISA (mAb-based)
Shibata, Hiroko, et al. "Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies and related product in Japanese patients with rheumatoid arthritis and their clinical impact." European Journal of Pharmaceutical Sciences (2025): 107357
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-ETA) Etanercept ELISAShikari® (Q-GOL) Golimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Huang, Bo-Han, et al. "Early Anti-Drug Antibodies Predict Adalimumab Response in Juvenile Idiopathic Arthritis." International Journal of Molecular Sciences 26.3 (2025): 1189.
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation
Akçadağ, Gülşah, et al. "Study on Cloning and Expression of TNF-α Variants in E. coli: Production, Purification, and Interaction with Anti-TNF-α Inhibitors." Protein and Peptide Letters 31.5 (2024): 395-408.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-ETA) Etanercept ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Kita, Toshihiro, et al. "Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial." Journal of Gastroenterology and Hepatology 37.11 (2022): 2051-2059.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Orts, Beatriz, et al. "Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease." Frontiers in Pharmacology 12 (2022): 795272.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Liu, Zheng, et al. "Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: a prospective cohort study in 107 children." Journal of Crohn's and Colitis 16.12 (2022): 1835-1844.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Little, Robert D., et al. "De-escalation from dose-intensified anti-TNF therapy is successful in the majority of IBD patients at 12 months." Digestive Diseases and Sciences 67 (2022): 259-262.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Linares, Raquel, et al. "Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease." Biomedicine & Pharmacotherapy 147 (2022): 112653.
Shikari® (Q-ADA) Adalimumab ELISA
Kim, Eun Sil, et al. "Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients." Gut and Liver 16.1 (2022): 71.
Shikari® (Q-ADA) Adalimumab ELISA
Iwasaki, Takeshi, et al. "Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis." Frontiers in immunology 13 (2022): 901437.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-ETA) Etanercept ELISAShikari® (S-ATE) Anti-Etanercept ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
De Gregorio, Michael, et al. "Higher anti-tumor necrosis factor-α levels correlate with improved radiologic outcomes in Crohn’s perianal fistulas." Clinical Gastroenterology and Hepatology 20.6 (2022): 1306-1314.
Shikari® (Q-ADA) Adalimumab ELISA
Wu, Yang, et al. "Management Decisions in Crohn’s Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels." Crohn's & Colitis 360 3.3 (2021): otab042.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Pękala, Anna, Rafał Filip, and David Aebisher. "Anti-drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: A prospective cohort study." Journal of Clinical Medicine 10.12 (2021): 2653.
Shikari® (Q-REMS) Infliximab biosimilar ELISAShikari® (Q-ADA) Adalimumab ELISA
Kim, Mi Jin, et al. "Therapeutic drug monitoring of adalimumab during long-term follow-up in paediatric patients with crohn Disease." Journal of Pediatric Gastroenterology and Nutrition 72.6 (2021): 870-876.
Shikari® (Q-ADA) Adalimumab ELISA
Judit Szántó, Kata, et al. "Advances in the optimisation of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists." Expert Opinion on Biological Therapy (2021).
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Alañón Pardo, M. M., et al. "Monitorización farmacocinética de terapias biológicas en enfermedad inflamatoria intestinal." Revista de la OFIL 31.1 (2021): 49-57.
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmationShikari® (Q-ATI) Anti-Infliximab ELISA
Choi, So Yoon, et al. "Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in pediatric Crohn's disease patients." Journal of Korean Medical Science 35.16 (2020).
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA
Zapater, Pedro, et al. "Actual anti-TNF Trough levels relate to serum IL-10 in drug-responding patients with Crohn’s disease." Inflammatory bowel diseases 25.8 (2019): 1357-1366.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Vasudevan, Abhinav, et al. "Higher mucosal healing with tumor necrosis factor inhibitors in combination with thiopurines compared to methotrexate in Crohn’s disease." Digestive Diseases and Sciences 64 (2019): 1622-1631.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Flanagan, E., et al. "Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD." J Crohn’s Colitis 13 (2019): S449-S45050.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Duricova, Dana, et al. "Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation." Inflammatory bowel diseases 25.4 (2019): 789-796.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Sugita, Naoko, et al. "Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease." Journal of Gastroenterology and Hepatology 33.3 (2018): 631-637.
Shikari® (Q-ADA) Adalimumab ELISA
Shirai, Shimpei, et al. "Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy." Inflammatory bowel diseases 24.5 (2018): 1082-1091.
Shikari® (Q-ADA) Adalimumab ELISA
Ward, M. G., et al. "Intra‐patient variability in adalimumab drug levels within and between cycles in Crohn's disease." Alimentary Pharmacology & Therapeutics 45.8 (2017): 1135-1145.
Shikari® (Q-ADA) Adalimumab ELISA
Piñero, Paula, et al. "IL26 modulates cytokine response and anti-TNF consumption in Crohn’s disease patients with bacterial DNA." Journal of Molecular Medicine 95 (2017): 1227-1236.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Kui, Róbert, et al. "Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)‐α level and the efficacy of TNF‐inhibitor therapy in psoriasis." The Journal of Dermatology 43.9 (2016): 1018-1023.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Julsgaard, Mette, et al. "Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection." Gastroenterology 151.1 (2016): 110-119.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Gutiérrez, Ana, et al. "Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with Crohn’s disease." Official journal of the American College of Gastroenterology| ACG 111.4 (2016): 529-540.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Gibellini, Lara, et al. "Anti-TNF-α drugs differently affect the TNFα-sTNFR system and monocyte subsets in patients with psoriasis." PLoS One 11.12 (2016): e0167757.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-ETA) Etanercept ELISAShikari® (S-ATE) Anti-Etanercept ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Juanola, Oriol, et al. "Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease." Journal of gastroenterology 50 (2015): 758-768.
Shikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Bodini, Giorgia, et al. "Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice." Official journal of the American College of Gastroenterology| ACG 110.3 (2015): 472-
Shikari® (Q-ADA) Adalimumab ELISA
Khanna, Reena, et al. "Therapeutic drug monitoring of TNF antagonists in inflammatory bowel disease." Gastroenterology & Hepatology 10.8 (2014): 478.
Shikari® (Q-ADA) Adalimumab ELISA
Gutiérrez, Ana, et al. "Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease." Gut 63.2 (2014): 272-280.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov A.A., Cherkasova M.V., Nasonov E.L. Efficacy Of Adalimumab In Early Rheumatoid Arthritis In Relation To Its Serum Level And The Presence Of Anti-Drug Antibody, Rheumatology Science and Practice, 52(6):624–630, 2014.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA
Takahashi, Hidetoshi, et al. "Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis." The Journal of dermatology 40.1 (2013): 39-42.
Shikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Romero, Gabriela, et al. "Poly (L actide‐co‐G lycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of AntiTNF‐α." Macromolecular bioscience 13.7 (2013): 903-912.
Shikari® (Q-ADA) Adalimumab ELISA
Bortlik, Martin, et al. "Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study." Scandinavian journal of gastroenterology 48.8 (2013): 951-958.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Bodini, Giorgia, et al. "Sa2045 Relationship between drug serum concentration and clinical activity in patients with Crohn disease who achieved remission with adalimumab-a prospective study." Gastroenterology 5.142 (2012): S-388.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation
Efficacy of tumor necrosis factor-α inhibitors in the treatment of various immunoinflammatory diseases:focus on immunogenicity/Эффективность ингибиторов фактора некроза опухоли α в лечении различных иммуновоспалительных заболеваний:фокус на иммуногенность
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-CERT) Certolizumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Ready to order, or need technical guidance?
Our team can support kit selection, technical-information requests and research-programme quotations. SHIKARI® ELISA kits are developed and manufactured by Matriks Biotek in Ankara, with European commercial and research support from Matrix Biotek in Barcelona.